Investigation of complete-response rate of intralesional immunotherapy with Candida antigen for the treatment of molluscum contagiosum

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180411039265N2

Enrollment

Registered

2019-03-02

Start date

2018-08-15

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Molluscum contagiosum. Molluscum contagiosum

Interventions

Intervention group: Firstly, scratch test (prick test) with Candida antigen is performed on all patients in order to determine the level of type 1 hypersensitivity to Candida. Patients with negative p

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: acquisition of patient and parents' consent

Exclusion criteria

Exclusion criteria: Pregnant or lactating women Violation of initial safety conditions or iatrogenic decease Infection with HIV1 Increased sensitivity to Candida antigen Reception of any treatment in relation to molluscum during the past month

Design outcomes

Primary

Measure	Time frame
Complete-response, relative-response or no-response to the treatment of lesions. Timepoint: Monthly immunotherapy continues until the mucosal lesions completely disappear and for molluscums with less or no-response, it continues for a maximum of 6 treatment sessions. Method of measurement: Number and level of molluscums are written down.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaman Afkhami Ardakani

Mashhad University of Medical Sciences

Afkhamias951@mums.ac.ir+98 51 3802 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026